KMDA - Kamada Ltd Company Long-Term Liabilities

Graphic logo of Kamada Ltd (KMDA)

Kamada Ltd. (KMDA) develops drugs for the therapy of orphan diseases. This price chart reflects the impact of implementing robotic filling and fractionation systems, which reduces the influence of human error. The current metric stands at 0.01. Sales of plasma proteins and antidotes in the US are driving margin growth. Stable demand for life-saving medications renders this business a defensive asset independent of market cycles.

Company Long-Term Debts: Kamada Ltd. (KMDA) for 07/04/2022 - 10/29/2026

Kamada Corp (KMDA) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price kamada.com|KMDA - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Kamada|KMDA - Enterprise Value
- shareholders' equity book value data:
Net Assets per Share Kamada|KMDA - Book Capitalization|Market Capitalization to Book Value Ratio kamada.com|KMDA - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Kamada Ltd.|KMDA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Kamada Pharma|KMDA - Company Total Debt|Debts to Book Capitalization Ratio Kamada|KMDA - Company Long-Term Debts|Short-Term Debt Kamada
Fundamental company valuation:kamada.com, KMDA
Manufactured products of Kamada Ltd.

The specifics of Kamada Ltd. (KMDA) biopharmaceutical production require capital-intensive investments in cold chain infrastructure and global raw material logistics. This metric captures the aggregate of long-term liabilities, reflecting the liability structure and the level of debt load over a multi-year horizon. Analyzing this metric allows for an assessment of the interest burden risk should market conditions shift. The trend in the company's long-term debt serves as an indicator of the balance between capacity expansion and financial stability.

Who Kamada Ltd. competes with

vrtx.com (VRTX) - Long-Term Debt|Alnylam - Company Long-Term Debts|Insmed Inc. (INSM) - Company Long-Term Liabilities|UTHR: Company Long-Term Debts|BMRN - Long-Term Debt Volume|BBIO (BridgeBio Pharma, Inc.) - Company Long-Term Debts|Company Long-Term Debts BGM Group Corp|Company Long-Term Debt Cogent Biosciences, Inc. (COGT)|Company Long-Term Debt XERS (Xeris Biopharma Holdings, Inc.)|Company Long-Term Debts KROS (Keros Pharma)|Long-Term Debt Volume Arcturus Corp (ARCT)|ETON: Company Long-Term Liabilities|Long-Term Liabilities FULC|ABEO: Company Long-Term Debts|Long-Term Debt Mereo BioPharma Group plc (MREO)|PLX (Protalix) - Company Long-Term Debts|Company Long-Term Indebtedness PLRX (Pliant Rx)|Company Long-Term Liabilities APLT (Applied Therapeutics, Inc.)|RNTX (aileronrx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Gelteq GELS|AYTU (Aytu BioPharma Inc) - Long-Term Liabilities|Chemomab - Company Long-Term Debts|Company Long-Term Loans and Borrowings SRXH (SRx Health Solutions Inc.)|PLRZ: Company Long-Term Debts|Aeterna Zentaris Inc. (AEZS) - Company Long-Term Debts|Company Long-Term Debt Cyclo Therapeutics, Inc.|INZY: Company Long-Term Loans and Borrowings|Company Long-Term Debt Reneo Pharma (RPHM)|Company Long-Term Liabilities COSCIENS Bio CSCI